Most of us share a common misconception that our disorder is a result of some kind of character failing.
But what if it wasn’t your lack of willpower or supposed bad choices holding you back? What if there was a missing link in your body that, through no fault of your own, was harming you?
What if it’s your level of Akkermansia?
Prof. Willem M. de Vos and Prof. Patrice D. Cani discovered that Akkermansia muciniphila helps maintain a healthy gut microbiome.
Too little of this bacterium and the gut barrier begins to leak, allowing harmful toxins and fat to enter the body. But we can undo the damage by restoring the natural level of the bacterium.
Enter The
Akkermansia CompanyTM
Akkermansia, the missing link to overcoming lifestyle disorders
Produce a range of pioneering solutions that help people live healthier, happier lives
Accelerate scientific research and understanding of the medical application of Akkermansia
Start a global movement that helps liberate people from discomforting thoughts and help them to improve their health
We’re taking our message to all corners of the globe:
it’s not you, it’s your level of Akkermansia.
Our History
2004
Akkermansia muciniphila isolation, identification and characterisation by Prof. Willem M. de Vos (Wageningen University – The Netherlands) and his team.
2008-2013
Collaboration between the teams of Prof. Willem M. de Vos (Wageningen University – The Netherlands) and Prof. Patrice D. Cani (UCLouvain – Belgium).
They demonstrate the efficacy of Akkermansia muciniphila supplementation in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity.
2015
Demonstration of higher efficiency of the pasteurised Akkermansia muciniphila compared to the live bacterium in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity.
2015
First high-scale production of Akkermansia muciniphila at a quality level suitable to begin clinical studies. The ethical committee gives its approval for the Microbes4U study.
2019
Publication of the Microbes4U© study results in Nature Medicine : the first randomised double-blind placebo-controlled pilot study in human volunteers demonstrates that daily administration of pasteurised Akkermansia muciniphila for 3 months is safe, well tolerated and reduces cardiometabolic risk factors (pre-diabetes, hypercholesterolemia, low-grade inflammation).
2019
Application for the approval of pasteurised Akkermansia muciniphila as a novel food ingredient in the European Union.
2020
Publication of the toxicological safety evaluation of pasteurised Akkermansia muciniphila.
2021
First next generation bacterium to get EFSA approval.
Scientific Study
53%
of Europeans over 18 are overweight1
VIEW
1 Eurostat
2 EGCG Green Tea: helps with your weight control
3 Chromium: contributes to the maintenance of your normal blood glucose levels
